Bausch Health Cos Net Profit Margin 2012-2025 | BHC
Bausch Health Cos net profit margin from 2012 to 2025. Net profit margin can be defined as net Income as a portion of total sales revenue.
| Bausch Health Cos Net Profit Margin Historical Data | |||
|---|---|---|---|
| Date | TTM Revenue | TTM Net Income | Net Margin |
| 2025-12-31 | $10.27B | $0.16B | 1.53% |
| 2025-09-30 | $10.03B | $0.36B | 3.61% |
| 2025-06-30 | $9.86B | $0.10B | 0.99% |
| 2025-03-31 | $9.73B | $-0.04B | -0.41% |
| 2024-12-31 | $9.63B | $-0.05B | -0.48% |
| 2024-09-30 | $9.47B | $-0.18B | -1.88% |
| 2024-06-30 | $9.20B | $-0.47B | -5.12% |
| 2024-03-31 | $8.97B | $-0.46B | -5.07% |
| 2023-12-31 | $8.76B | $-0.59B | -6.76% |
| 2023-09-30 | $8.54B | $-0.96B | -11.27% |
| 2023-06-30 | $8.35B | $-0.19B | -2.23% |
| 2023-03-31 | $8.15B | $-0.36B | -4.38% |
| 2022-12-31 | $8.12B | $-0.23B | -2.77% |
| 2022-09-30 | $8.13B | $0.25B | 3.13% |
| 2022-06-30 | $8.19B | $0.04B | 0.52% |
| 2022-03-31 | $8.33B | $-0.41B | -4.89% |
| 2021-12-31 | $8.43B | $-0.95B | -11.24% |
| 2021-09-30 | $8.45B | $-1.17B | -13.84% |
| 2021-06-30 | $8.48B | $-1.29B | -15.18% |
| 2021-03-31 | $8.04B | $-1.02B | -12.66% |
| 2020-12-31 | $8.03B | $-0.56B | -6.98% |
| 2020-09-30 | $8.04B | $-1.92B | -23.92% |
| 2020-06-30 | $8.11B | $-2.04B | -25.19% |
| 2020-03-31 | $8.60B | $-1.89B | -21.96% |
| 2019-12-31 | $8.60B | $-1.79B | -20.79% |
| 2019-09-30 | $8.50B | $-0.62B | -7.25% |
| 2019-06-30 | $8.43B | $-0.92B | -10.88% |
| 2019-03-31 | $8.40B | $-1.62B | -19.27% |
| 2018-12-31 | $8.38B | $-4.15B | -49.50% |
| 2018-09-30 | $8.42B | $-3.29B | -39.08% |
| 2018-06-30 | $8.51B | $-1.64B | -19.28% |
| 2018-03-31 | $8.61B | $-0.81B | -9.35% |
| 2017-12-31 | $8.72B | $2.40B | 27.56% |
| 2017-09-30 | $8.96B | $1.38B | 15.35% |
| 2017-06-30 | $9.22B | $-1.14B | -12.39% |
| 2017-03-31 | $9.41B | $-1.41B | -14.95% |
| 2016-12-31 | $9.67B | $-2.41B | -24.90% |
| 2016-09-30 | $10.03B | $-2.28B | -22.73% |
| 2016-06-30 | $10.34B | $-1.01B | -9.79% |
| 2016-03-31 | $10.65B | $-0.76B | -7.16% |
| 2015-12-31 | $10.45B | $-0.29B | -2.79% |
| 2015-09-30 | $9.91B | $0.60B | 6.02% |
| 2015-06-30 | $9.18B | $0.82B | 8.95% |
| 2015-03-31 | $8.49B | $1.00B | 11.79% |
| 2014-12-31 | $8.21B | $0.88B | 10.72% |
| 2014-09-30 | $8.05B | $0.50B | 6.24% |
| 2014-06-30 | $7.53B | $-0.75B | -9.90% |
| 2014-03-31 | $6.59B | $-0.86B | -13.07% |
| 2013-12-31 | $5.77B | $-0.87B | -15.01% |
| 2013-09-30 | $4.63B | $-1.08B | -23.32% |
| 2013-06-30 | $3.97B | $-0.10B | -2.47% |
| 2013-03-31 | $3.69B | $-0.13B | -3.55% |
| 2012-12-31 | $3.48B | $-0.12B | -3.33% |
| 2012-09-30 | $3.21B | $0.03B | 0.90% |
| 2012-06-30 | $2.93B | $0.06B | 2.12% |
| 2012-03-31 | $2.72B | $0.14B | 5.15% |
| 2011-12-31 | $2.43B | $0.16B | 6.55% |
| 2011-09-30 | $2.29B | $0.07B | 3.14% |
| 2011-06-30 | $1.90B | $-0.18B | -9.33% |
| 2011-03-31 | $1.53B | $-0.20B | -13.03% |
| 2010-12-31 | $1.18B | $-0.21B | -17.60% |
| 2010-09-30 | $0.91B | $-0.10B | -11.45% |
| 2010-06-30 | $0.91B | $0.14B | 15.77% |
| 2010-03-31 | $0.87B | $0.13B | 15.44% |
| 2009-12-31 | $0.82B | $0.18B | 21.44% |
| 2009-09-30 | $0.76B | $0.22B | 29.30% |
| 2009-06-30 | $0.73B | $0.23B | 31.69% |
| 2009-03-31 | $0.72B | $0.18B | 25.24% |
| 2008-12-31 | $0.76B | $0.20B | 26.32% |
| 2008-09-30 | $0.78B | $0.05B | 6.03% |
| 2008-06-30 | $0.79B | $0.07B | 8.26% |
| 2008-03-31 | $0.80B | $0.16B | 19.65% |
| 2007-12-31 | $0.84B | $0.20B | 23.25% |
| 2007-09-30 | $0.95B | $0.34B | 36.22% |
| 2007-06-30 | $1.05B | $0.22B | 21.09% |
| 2007-03-31 | $1.10B | $0.23B | 21.31% |
| 2006-12-31 | $1.07B | $0.20B | 19.03% |
| 2006-09-30 | $1.05B | $0.21B | 19.87% |
| 2006-06-30 | $1.02B | $0.37B | 35.98% |
| 2006-03-31 | $0.98B | $0.29B | 29.47% |
| 2005-12-31 | $0.94B | $0.24B | 25.27% |
| 2005-09-30 | $0.93B | $0.16B | 17.56% |
| 2005-06-30 | $0.89B | $0.11B | 12.53% |
| 2005-03-31 | $0.88B | $0.15B | 17.26% |
| 2004-12-31 | $0.89B | $0.16B | 18.15% |
| 2004-09-30 | $0.81B | $0.02B | 2.35% |
| 2004-06-30 | $0.81B | $-0.02B | -2.23% |
| 2004-03-31 | $0.82B | $-0.06B | -7.69% |
| 2003-12-31 | $0.82B | $-0.02B | -2.55% |
| 2003-09-30 | $0.86B | $-0.03B | -3.25% |
| 2003-06-30 | $0.86B | $0.03B | 3.97% |
| 2003-03-31 | $0.82B | $0.10B | 11.89% |
| 2002-12-31 | $0.79B | $0.09B | 11.17% |
| 2002-09-30 | $0.73B | $0.17B | 23.66% |
| 2002-06-30 | $0.67B | $0.13B | 19.40% |
| 2002-03-31 | $0.62B | $0.11B | 17.93% |
| 2001-12-31 | $0.58B | $0.09B | 14.92% |
| 2001-09-30 | $0.51B | $0.08B | 16.44% |
| 2001-06-30 | $0.44B | $-0.05B | -11.99% |
| 2001-03-31 | $0.37B | $-0.08B | -20.38% |
| 2000-12-31 | $0.30B | $-0.11B | -37.50% |
| 2000-09-30 | $0.26B | $-0.06B | -24.05% |
| 2000-06-30 | $0.22B | $0.06B | 26.03% |
| 2000-03-31 | $0.20B | $0.05B | 24.10% |
| 1999-12-31 | $0.18B | $0.06B | 35.23% |
| 1999-09-30 | $0.15B | $0.05B | 35.37% |
| 1999-06-30 | $0.13B | $0.05B | 36.92% |
| 1999-03-31 | $0.12B | $0.05B | 38.66% |
| 1998-12-31 | $0.11B | $0.05B | 40.71% |
| 1998-09-30 | $0.10B | $0.04B | 43.14% |
| 1998-06-30 | $0.09B | $0.04B | 42.55% |
| 1998-03-31 | $0.09B | $0.04B | 42.53% |
| 1997-12-31 | $0.08B | $0.04B | 43.21% |
| 1997-09-30 | $0.07B | $0.03B | 42.03% |
| 1997-06-30 | $0.07B | $0.03B | 39.39% |
| 1997-03-31 | $0.07B | $0.03B | 37.88% |
| 1996-12-31 | $0.07B | $0.02B | 35.82% |
| 1996-09-30 | $0.06B | $0.02B | 32.26% |
| 1996-06-30 | $0.05B | $0.02B | 31.91% |
| 1996-03-31 | $0.03B | $0.01B | 28.13% |
| 1995-12-31 | $0.02B | $0.01B | 23.81% |
| 1995-09-30 | $0.02B | $0.00B | 19.05% |
| 1995-06-30 | $0.02B | $0.00B | 13.64% |
| 1995-03-31 | $0.02B | $0.00B | 9.52% |
| 1994-12-31 | $0.02B | $0.01B | 52.94% |
| 1994-06-30 | $0.01B | $0.01B | 111.11% |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical - Generic Drugs | $2.086B | $10.266B |
| Bausch Health Companies Inc. develops, manufactures and markets a wide array of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products along with medical devices such as contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices in the therapeutic areas of eye-health, gastroenterology (GI), and dermatology. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Teva Pharmaceutical Industries (TEVA) | Israel | $35.437B | 10.97 |
| BridgeBio Pharma (BBIO) | United States | $14.460B | 0.00 |
| Dr Reddy's Laboratories (RDY) | India | $11.109B | 17.29 |
| Aspen Pharmacare (APNHY) | South Africa | $3.708B | 0.00 |
| Supernus Pharmaceuticals (SUPN) | United States | $2.918B | 22.33 |
| Taysha Gene Therapies (TSHA) | United States | $1.290B | 0.00 |
| Amphastar Pharmaceuticals (AMPH) | United States | $0.924B | 7.28 |
| Personalis (PSNL) | United States | $0.630B | 0.00 |
| Assembly Biosciences (ASMB) | United States | $0.451B | 0.00 |
| Sol-Gel Technologies (SLGL) | Israel | $0.210B | 0.00 |
| Metagenomi Therapeutics (MGX) | United States | $0.052B | 0.00 |
| Evoke Pharma (EVOK) | United States | $0.019B | 0.00 |
| Teligent (TLGT) | United States | $0.000B | 0.00 |